Profile data is unavailable for this security.
About the company
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2023
- Employees3.00k
- LocationEndo Inc1400 Atwater DriveMALVERN 19355United StatesUSA
- Phone+1 (484) 216-0000
- Fax+1 (302) 655-5049
- Websitehttps://www.endo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | 555.46m | -8.77m | 1.20bn | 642.00 | -- | 2.96 | 23.19 | 2.15 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Innoviva Inc | 352.75m | 64.59m | 1.20bn | 112.00 | 27.84 | 1.79 | 11.48 | 3.40 | 0.6879 | 0.6879 | 4.78 | 10.68 | 0.2916 | 1.14 | 4.44 | 3,149,509.00 | 5.34 | 26.24 | 5.98 | 28.53 | 87.93 | -- | 18.31 | 76.84 | 1.64 | 1.93 | 0.4011 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.21bn | 2.65k | -- | 0.3373 | -- | 1.49 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Ocular Therapeutix Inc | 61.44m | -174.34m | 1.38bn | 267.00 | -- | 3.93 | -- | 22.41 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Harrow Inc | 169.14m | -33.41m | 1.52bn | 315.00 | -- | 26.35 | -- | 9.00 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 384.10m | -9.07m | 1.54bn | 297.00 | -- | 3.51 | -- | 4.00 | -0.1584 | -0.1584 | 5.28 | 6.06 | 0.7398 | 1.94 | 27.51 | 1,293,259.00 | -1.75 | -16.49 | -2.04 | -18.72 | 86.31 | -- | -2.36 | -53.64 | 2.95 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Immunocore Holdings PLC - ADR | 296.55m | -47.11m | 1.62bn | 497.00 | -- | 4.27 | -- | 5.45 | -0.9494 | -0.9494 | 5.88 | 7.55 | 0.3593 | 0.541 | 5.68 | 596,681.90 | -5.71 | -27.55 | -7.45 | -36.82 | 99.38 | -- | -15.89 | -97.12 | 3.76 | -- | 0.5373 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Tarsus Pharmaceuticals Inc | 129.62m | -134.34m | 1.84bn | 244.00 | -- | 7.76 | -- | 14.16 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.87bn | 3.00k | -- | 1.02 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 1.94bn | 246.00 | 16.13 | 3.26 | 13.23 | 2.85 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 2.00bn | 652.00 | 33.91 | 1.99 | 13.99 | 3.07 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Amphastar Pharmaceuticals Inc | 723.55m | 157.72m | 2.20bn | 1.76k | 15.13 | 3.02 | 10.41 | 3.04 | 3.01 | 3.01 | 13.79 | 15.04 | 0.4684 | 2.83 | 5.60 | 410,873.90 | 10.28 | 9.42 | 11.88 | 11.56 | 52.98 | 47.83 | 21.95 | 15.23 | 2.61 | 9.42 | 0.4506 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Ligand Pharmaceuticals Inc | 152.42m | 45.24m | 2.25bn | 58.00 | 49.12 | 2.66 | 27.88 | 14.78 | 2.43 | 2.43 | 8.25 | 44.84 | 0.1768 | 0.4689 | 4.34 | 2,627,966.00 | 5.25 | 12.32 | 5.37 | 12.99 | 93.52 | 81.65 | 29.68 | 80.32 | 11.81 | -- | 0.00003 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Twist Bioscience Corp | 312.97m | -208.73m | 2.51bn | 923.00 | -- | 5.26 | -- | 8.01 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.56bn | 167.00 | 18.33 | 3.88 | 14.21 | 5.56 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Data as of Nov 22 2024. Currency figures normalised to Endo Inc's reporting currency: US Dollar USD
14.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Franklin Advisers, Inc.as of 30 Sep 2024 | 5.20m | 6.81% |
| Marathon Asset Management LPas of 28 Oct 2024 | 3.93m | 5.14% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 1.29m | 1.70% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 511.67k | 0.67% |
| Eaton Vance Managementas of 30 Sep 2024 | 38.59k | 0.05% |
| Nykredit Bank A/S (Investment Management)as of 31 Aug 2024 | 19.81k | 0.03% |
| Eaton Vance Advisers International Ltd.as of 30 Sep 2024 | 3.65k | 0.01% |
| abrdn, Inc.as of 30 Jun 2024 | 2.61k | 0.00% |
| Duff & Phelps Investment Management Co.as of 30 Aug 2024 | 1.93k | 0.00% |
| Kayne Anderson Rudnick Investment Management LLCas of 28 Jun 2024 | 1.79k | 0.00% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
